GlassScriptPhysician profile
David Edward Samara
NPI 1962401174
$612.49
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $99.10 · 2021: $142.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $274.43 | 2019-2021 | |
| Adlon Therapeutics L.P. | $70.77 | 2019-2021 | |
| Cranial Technologies, INC | $63.49 | 2019 | |
| Shire North American Group INC | $36.32 | 2019 | |
| Neos Therapeutics, LP | $35.22 | 2019 | |
| Genentech USA, INC. | $27.42 | 2019-2020 | |
| Sobi, INC | $22.90 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $21.26 | 2020 | |
| Glaxosmithkline, LLC. | $18.33 | 2020 | |
| Abbvie INC. | $18.28 | 2019 | |
| Merck Sharp & Dohme LLC | $12.18 | 2019 | |
| Mission Pharmacal Company | $11.89 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Samara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.